Safeguarding the Brain of our smallest Children

SafeBoosC-IIIv

Cerebral oximetry in newborns receiving invasive mechanical ventilation.

Trial phase	Phase III
Protocol version and date	Version 2.1 (26.11.2024)

Applicable protocol registration numbers ClinicalTrials.gov identifier: NCT05907317
Ethics committee number: 2402572

Sponsor Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Denmark, Phone: +45 26186242, Email: janus.jakobsen@ctu.dk

Study centre: Multicentre; international

Abstract

Background

Newborns in need of invasive mechanical ventilation are at high risk of a detrimental outcome, not only due to the underlying condition, but also due to complications from the invasive mechanical ventilation itself (1, 2). Such complications include pneumothorax, ventilation associated pneumonia, and hyperventilation causing vasoconstriction of the cerebral vasculature and possibly brain ischaemia (3). Summary data on outcomes is not easily available, but during 2019 death before discharge occurred in 41/500 (8.2%) newborns, born at more than 28 weeks of gestation and in need of invasive mechanical ventilation during the neonatal period, in 10 neonatal units within the SafeBoosC consortium. A meta-analysis including 895 neonates from 23 non-randomised trials, undergoing surgery for non-cardiac congenital anomalies, found a deficit in intelligence quotient of 0.5 standard deviations below the population average (4). Additionally, data from a Danish national cohort, showed that 18% of children who underwent invasive mechanical ventilation during the neonatal period, needed special educational support in primary school, which is 2.5 times more often than normal (Wiingreen et al. unpublished data).

Thus, invasive mechanically ventilated newborns are a high-risk population. Given the instability of the newborn's pulmonary and circulatory physiology, it is possible that the addition of measuring the oxygenation of the brain, by non-invasive near-infrared light technology (cerebral oximetry) plus a treatment guideline, as an addition to the complex treatment and monitoring regimes for these newborns, may increase the chance of surviving without neurodevelopmental impairment.

Objectives

The objective of the SafeBoosC-IIIv trial is to evaluate cerebral oximetry added to usual care versus usual care in newborns receiving invasive mechanical ventilation. The hypothesis for step one is that the intervention will increase the number of hospital-free days within 90 days of randomisation. The hypothesis for step two is that the intervention will decrease a composite outcome of death or moderate to severe neurodevelopmental disability and/or increase the mean PARCA-R non-verbal cognitive score at two years of corrected age.

Trial design

SafeBoosC-IIIv will be an investigator-initiated, multinational, randomised, pragmatic phase III clinical trial. The trial will be conducted in two steps. In step one, 1,610 newborns will be randomised, and the outcomes will be assessed 90 days after randomisation. Funding has been obtained for step one. If further funding is obtained, we will continue to include newborns until a total of 3,000 newborns are randomised and then follow them up at two years of corrected age (step two). Randomisation will be performed in neonatal intensive care units across many countries. Data managers, statisticians, and conclusion drawers will be blinded.

Inclusion and exclusion criteria

Inclusion criteria will be:

- Newborns with gestational age more than or equal to 28+0
- Postnatal age less than 28 days
- Expected to receive invasive mechanical ventilation (intubation) for at least 24 hours, as judged by the physician intending to randomise
- Parental informed consent unless the centre has chosen to use 'opt-out' or deferred consent as consent method
- A cerebral oximeter available so monitoring can be started within six hours after initiation of invasive mechanical ventilation

Exclusion criteria will be:

- Suspicion of or confirmed brain injury or disorder (e.g. severe hypoxic-ischemic encephalopathy, intraventricular haemorrhage grade 3 or 4, cerebral malformation, genetic or metabolic disease)
- Suspicion or diagnosis of congenital heart malformations likely to require surgery

Randomisation and interventions

Participants will be randomised through central web-based randomisation stratified by neonatal intensive care unit; gestational age (lower gestational age (≤ 34 weeks) / higher gestational age (> 34 weeks)), and surgery (newborns in need of invasive mechanical ventilation due to a surgery (yes/no)) at Copenhagen Trial Unit.

Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.

The control group will receive invasive mechanical ventilation without access to cerebral oximetry (usual care).

Outcomes

The primary outcome for step one will be hospital-free days within 90 days of randomisation. This outcome will be assessed by a blinded investigator.

Based on a relative risk reduction of death of 5% and an absolute increase of 3 days in the estimate of hospital-free days of the surviving participants (considered clinically relevant) with an alpha of 0.05 and a power of 90% using the van Elteren test, we would need to include 1,610 participants.

There will be two co-primary outcomes for step two: 1) a composite of death or moderate-to-severe neurodevelopmental disability and 2) non-verbal cognitive score of Parent Report of Children's Abilities-Revised (PARCA-R).

To test a reduction in death or moderate to severe neurodevelopment disability from 20% to 16% between the experimental and control group, at an alpha-level of 2.5% and a power of 80%, a total of 1,500 participants in each group, i.e. a total of 3,000, is needed. This corresponds to a relative risk reduction of 20%.

Trial duration

Recruitment is expected to begin in January 2025 and expected to be completed within 29 months. If funding is obtained for step two, recruitment will continue for another 20 months.

SafeBoosC-IIIv trial flow chart



Administrative information

Sponsor

Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Denmark.
Phone: +45 26186242, Email: janus.jakobsen@ctu.dk

Steering Committee

SafeBoosC-IIIv is led by a Steering Committee comprising the Copenhagen SafeBoosC-IIIv project team, including Caroline Kamp (trial manager, Copenhagen Trial Unit)/Johanne Juul Petersen (alternate trial manager, Copenhagen Trial Unit), Gorm Greisen, all national coordinators, and Janus Christian Jakobsen (sponsor, Copenhagen Trial Unit). Decisions will be made by a simple majority.

Executive Steering Committee

The Executive Steering Committee is responsible for the day-to-day management and will comprise the Copenhagen SafeBoosC-IIIv project team, including Caroline Kamp (trial manager, Copenhagen Trial Unit)/Johanne Juul Petersen (alternate trial manager, Copenhagen Trial Unit), Gorm Greisen, Adelina Pellicer, Gunnar Naulaers, Eugene Dempsey, Gitte Hahn, and Janus Christian Jakobsen (sponsor, Copenhagen Trial Unit).

National coordinators

To be appointed

Independent Data Monitoring and Safety Committee (DMSC)

Andrew Whitelaw, University of Bristol
James Boardman, University of Edinburgh
Theis Lange, University of Copenhagen

Protocol amendments

Version	Date	Changes	Rationale
1.0		Initial version	
2.0	18.06.2024	• Changed to include step one and step two.	• Accommodate new trial setup following new central funding.
2.1	26.11.2024	• Rephrased inclusion and exclusion criteria. • Rephrased local monitoring plan. • Rephrased assessment of primary outcome. • Corrected timepoint of assessing serious adverse reactions. • Updated layout.	• Clarified inclusion and exclusion criteria based on recommendations from clinicians. • The local monitoring plan was rephrased from 'GCP monitoring' to 'Local monitoring plan based on ICH-GCP principles'. All procedures remain the same. • Assessment of the primary outcome was rephrased to clarify follow-up through clinical records and contact with parents. • Timepoint of assessing serious adverse reactions was changed from 90 days after randomisation to end of monitoring.

Table of contents

1 Introduction and background

1.1 The population and condition

Current standard of care of newborns in need of invasive mechanical ventilation, involves several different interventions (5). The criteria for initiation of invasive mechanical ventilation vary among neonatal intensive care units. In general, invasive mechanical ventilation is initiated when respiratory failure occurs, usually indicated by one or more of the following: hypercapnia, hypoxia or severe apnoea (3). In surgical patients, pain and/or analgesia may contribute to the need for invasive mechanical ventilation (6). It is commonly used for the following conditions in the near-term or term newborns: respiratory distress syndrome and pulmonary failure, congenital diaphragmatic hernia, other major congenital malformations and acute abdominal surgical conditions, sepsis, pneumonia, meningitis, persistent pulmonary hypertension, meconium aspiration syndrome, congenital cardiac anomalies, anticonvulsant treatment and hypoxic-ischaemic encephalopathy (5).

1.1.1 Current clinical management

Newborns receiving invasive mechanical ventilation are routinely monitored by continuous recording of heart rate, respiratory waveform, pulse oximetry, often invasive arterial blood pressure and often transcutaneous oxygen and carbon dioxide tension (7). The ventilator usually provides monitoring of respiratory pressures and volumes. Adjustments of the respiratory support is frequently needed and circulatory support may be needed with inotropes, vasopressors or volume expansion with saline, albumin or red blood cells (8).

1.2 Cerebral oximetry by near-infrared spectroscopy

Cerebral oximetry by near-infrared spectroscopy is a non-invasive technology that enables estimation of the tissue oxygenation in the brain (9). Cerebral oximetry uses the relative transparency of human tissue to light in the near-infrared region of the electromagnetic spectrum. Cerebral oximeters provide an absolute value of tissue oxygenation (rStO2), expressed as a ratio of oxygenated to total haemoglobin, in the tissue underlying a given monitoring sensor (10). As the distance from the skin to the brain surface is less than 6 millimetres in newborns (11), cerebral oximetry is particularly suitable for monitoring cerebral oxygenation in these patients.

Cerebral oximetry is based on the same principles as the widely used pulse oximetry, but whereas pulse oximetry uses only a pulsatile signal and thereby selectively measures the oxygen saturation in arterial blood, cerebral oximetry measures the light attenuation of the tissue as a whole, and the estimate of oxygen haemoglobin saturation is influenced by the blood in all types of vessels. This means that venous blood contributes more to the cerebral oximetry signal than arterial blood, since anatomically, venous blood has a greater volume within tissues. The ratio of

venous and arterial contribution is generally assumed to be 75:25, although this has been found to differ between and within newborns (12). Therefore, it is not surprising that cerebral tissue oxygenation has shown only a fair correlation with the saturation in cerebral venous blood, drawn from the jugular bulb (13). The Bland-Altman limit of agreement is ±15% to 20% (14, 15). However, tissue oxygenation (rStO2) is volume-weighted across areas with high or low oxygen extraction, whereas jugular bulb saturation is flow-weighted, and therefore, venous oxygen saturation cannot be considered a 'gold standard'.

1.3 Tissue oxygenation as a measure of cardiac output

Monitoring of cardiac output or tissue blood flow is not routinely feasible in newborns. Monitoring of heart rate and blood pressure are indirect measures of cardiac function, but the correlation to cardiac output is weak. Clinician performed echocardiography may be used to judge cardiac function intermittently, depending on availability of time and competence (16). Electrical cardiometry can, in addition, potentially provide non-invasive continuous hemodynamic monitoring. However, there are no clinical evidence on clinically relevant outcomes yet (16).

Cerebral tissue oxygenation correlates with cardiac output (17). Therefore, apart from being an indicator of oxygen sufficiency of the brain, it may serve a dual purpose also as an indicator of cardiac output and thus, be of relevance for oxygen sufficiency of other organs, such as the liver, kidney and heart and a low cerebral oxygenation might also be an indication to perform an echocardiography. Better management of low cardiac output may reduce the risk of dysfunction of these organs and thereby, reduce the risk of death.

1.4 Vascular reactions to circulatory stress

A mature autoregulation keeps the cerebral blood flow constant, despite fluctuations in perfusion pressure. It is accomplished by regulation of the arterial tone, so that low perfusion pressure results in vasodilation, and high perfusion pressure results in vasoconstriction (18). Autoregulation, however, may be impaired in ill newborns and thereby, operating at a reduced level (19). The characteristics of autoregulation in newborns is still not well defined but is affected by number of different factors, such as hypoxia or hypocapnia and circulatory stress (19).

On the systemic level, other organs such as the heart, and adrenal glands are also 'vital', and blood flow is maintained when systemic blood flow is low, while the arteries to non-vital organs, such as the skin and kidneys, vasoconstrict to maintain blood pressure, and direct circulating blood to the vital organs. This is partly mediated by the sympathetic nervous system (19). Sympathetic nerves, however, innervate the arteries of the immature forebrain (which is not vital

to the immediate survival) more effectively compared to adults (20) and therefore, sympathetic activation by central hypovolemia and poor filling of the heart may potentially contribute to brain ischaemic hypoxia.

1.5 Mechanisms of brain damage in newborns in need of invasive mechanical ventilation

Hypocapnia due to inadvertent hyperventilation causes vasoconstriction of the cerebral vasculature and may lead to cerebral ischaemia (21). This is an important cause of brain injury, in particularly periventricular leucomalacia and cerebral palsy in preterm infants (21). Although modern invasive mechanical ventilators offer better control of ventilation, carbon dioxide tension is still often very variable during invasive mechanical ventilation. Furthermore, cerebral vasoconstriction due to hypocapnia may interact with vasoconstriction due to circulatory stress, caused by the positive airway pressure during invasive mechanical ventilation, which impairs venous return and filling of the heart (22). Finally, cerebral blood flow combines with the oxygen carrying capacity of the blood, as determined by blood haemoglobin concentration and shifts in the oxygen-haemoglobin dissociation curve, to determine the cerebral oxygen delivery (23). If this falls short of demand, tissue oxygenation falls.

Hypoxic-ischaemic brain injury is also common in term newborns (24). Typically, it occurs during delivery and can lead to death or neurodevelopmental deficits such as cerebral palsy, cognitive deficits, attention deficit disorder, and major psychiatric disorders, which have long-term consequences for the affected children (25). Stroke is also relatively common (26).

1.5.1 Trials of clinical benefit in newborns receiving invasive mechanical ventilation

To our knowledge, no randomised clinical trials have evaluated cerebral oximetry added to usual care versus usual care in newborns receiving invasive mechanical ventilation. The COSGOD (Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth)-II and the SafeBoosC (Safeguarding the Brain of our smallest Children)-II randomised clinical trials have shown that it is possible to significantly reduce cerebral hypoxia, by adjusting intensive care based on cerebral oximetry in preterm infants (27, 28). The larger COSGOD-III and SafeBoosC-III trials have tested the effect of cerebral oximetry on clinical relevant outcomes, i.e. survival without severe brain injury (29, 30). COSGOD included preterm infants in the delivery room and SafeBoosC included extremely preterm infants during the first three days of life. Neither trial showed that treatment guided by cerebral oximetry monitoring was associated with a better clinical outcome.

It would be unfortunate, if cerebral oximetry was incorporated into routine intensive care of newborns without good evidence of benefits and harms. A meta-analysis by Hansen and colleagues (31) addresses the evidence of patient-relevant benefits of cerebral oximetry across all patient groups – extremely preterm infants to elderly adult patients undergoing cardiac surgery, and it concludes that there is yet insufficient data to confirm or reject the effects of cerebral oximetry on clinical relevant outcomes, and the addition of the coming results of COSGOD-III and SafeBoosC-III is unlikely to be decisive on this more general question. Thus, Trial Sequential Analysis shows a need for several thousand additional participants, to conclude that the clinical effect on cerebral oximetry is less than a 20% reduction of adverse outcomes. The SafeBoosC-IIIv trial can potentially fill this knowledge gab.

1.6 Benefits and risks

If the SafeBoosC-IIIv trial shows that cerebral oximetry will result in more hospital-free days, the benefits will be obvious. First, hospital-free days have value to patients in itself; it must be considered important to patients and their relatives to spend as little time as possible in the hospital. It may also be a valid surrogate outcome for other patient-important outcomes, as a low number of hospital-free days will likely correlate with complications and abilities to breathe and feed. Second, results based on hospital-free days reflect both incidences of deaths and the cumulated hospital burden (patients who die in hospital will experience no hospital-free days).

If the SafeBoosC-IIIv trial shows that cerebral oximetry is without effects or is harmful, such results will also benefit patients. If cerebral oximetry monitoring is without beneficial effects, clinical use result in waste of time and money that may be spent otherwise for the benefit of patients. Cerebral oximetry monitoring may theoretically cause harm. First, hypoxic values may result in unnecessary and potentially dangerous changes in cardiorespiratory support. Second, although near-infrared light is safe, the sensor may cause skin marks by pressure. Third, the placement of yet another sensor on the small body of a newborn is disturbing, and these patients are already stressed by care procedures.

2 Trial objective and hypothesis

The objective of the SafeBoosC-IIIv trial is to evaluate cerebral oximetry added to usual care versus usual care in newborns receiving invasive mechanical ventilation. The hypothesis for step one is that the intervention will increase the number of hospital-free days within 90 days of randomisation. The hypothesis for step two is that the intervention will decrease a composite outcome of death or moderate to severe neurodevelopmental disability and/or increase the mean PARCA-R non-verbal cognitive score at two years of corrected age.

3 Trial design

This is an investigator-initiated, multinational, randomised, pragmatic phase III clinical trial with a two parallel group design, that will enrol 1,610 newborns in step one. If funding is obtained, randomisation will continue until 3,000 newborns are enrolled (step two).

3.1 Randomisation

Participants will be randomised into either the experimental group or the control group. The ratio of allocation will be 1:1. The allocation will be computer-generated with varying block sizes and the randomisation will be stratified by neonatal intensive care unit, gestational age (lower gestational age (≤ 34 weeks) / higher gestational age (≥ 34 weeks)), and surgery (newborns in need of invasive mechanical ventilation due to a surgery (yes/no)), and will be concealed for all investigators. Randomisation will be centralised and web-based at Copenhagen Trial Unit.

A screening log will be kept at each site with a list of all admitted patients with gestational age more than or equal to 28+0, who were intubated and expected to be mechanically ventilated for more than 24 hours, at any time during the first 28 days after birth. The screening log will contain data on subject number, date of screening, gestational age (lower gestational age (<34 weeks) / higher gestational age (≥34 weeks)), expected surgery (yes/no), randomised (yes/no), and reason not randomised.

Singleton newborns will be randomised individually. Multiple birth newborns will be randomised individually, as it is not common that the twins or triplets will need invasive mechanical ventilation at the same time. A second twin can be enrolled when it meets the inclusion criteria if the parents can accept a separate randomisation.

3.2 Blinding

Due to the nature of the experimental intervention, clinical staff and the parents will not be blinded to group allocation. Data will be collected from clinical records and parents will be contacted (e.g. by phone and/or email). The primary outcome will be assessed by a blinded investigator. The principal investigator from each centre must develop a local blinding procedure, describing how blinding is achieved. Before the initiation of randomisation in each centre, the local blinding procedure must be approved by the trial manager. To support the principal investigators in this work, a Standard Operating Procedure with suggestions for blinding procedure has been developed.

Data managers, statisticians, and conclusion drawers will be blinded. Furthermore, survival status and hospital-free days will be source data verified for all participants at 90 days after randomisation during local monitoring visits. Two blinded statisticians at Copenhagen Trial Unit

will independently perform all statistical analyses using different statistical software programs (R and STATA). Both reports and third fused final report will be presented to the Steering Committee, and all three reports will be published as supplemental material. Discrepancies between the two reports will be discussed by the Steering Committee.

3.3 Trial timeline



4 Participants

We will include newborns based on the following inclusion and exclusion criteria.

4.1 Inclusion criteria

- Gestational age more than or equal to 28+0
- Postnatal age less than 28 days
- Expected to receive invasive mechanical ventilation (intubation) for at least 24 hours, as judged by the physician intending to randomise
- Parental informed consent unless the centre has chosen to use ‘opt-out’ or deferred consent as consent method
- A cerebral oximeter available so monitoring can be started within six hours after initiation of invasive mechanical ventilation

4.2 Exclusion criteria

- Suspicion of or confirmed brain injury or disorder (e.g. severe hypoxic-ischemic encephalopathy, intraventricular haemorrhage grade 3 or 4, cerebral malformation, genetic or metabolic disease)
- Suspicion or diagnosis of congenital heart malformations who is likely to need surgery

4.3 Participation in other trials

Participants included in the SafeBoosC-IIIv trial can participate in any other trial, on the condition that the trial does not:

- Allow clinical staff access to cerebral oximetry in the control group from inclusion in SafeBoosC-IIIv to the end of the intervention period or;
- Exclude a treatment that would be clearly indicated by the SafeBoosC treatment guideline during the intervention period in the experimental group.

All partners are encouraged to design substudies and draw on data collected by SafeBoosC-IIIv if such studies do not compromise the blinding of assessors or the equipoise of the trial. Substudies must be approved by the SafeBoosC-IIIv Steering Committee, if presenting results analysed according to randomisation group.

4.3.1 Participant discontinuation and withdrawal

The participants' parents are free to withdraw their newborn from the intervention at any time and to decline the use of any future data. For newborns included by deferred consent, the parents are also allowed to decline the use of previously registered data. A Standard Operating procedure outlining when and how participant data should be deleted, if requested by the parents, will be developed before initiation of the trial. Withdrawal from the intervention or decline of data usage will not have any consequences for the newborn's further treatment. Reasons for discontinuation, if offered by the parents, will be documented. The attending clinician can withdraw any participant from the trial intervention at any time, in case there are safety concerns. Reasons for withdrawal will be documented. There are no pre-specified criteria for discontinuation of participants from the trial. Discontinuation of participants from the trial will not result in replacement with new participants.

4.3.2 Recruitment feasibility

The feasibility of recruitment for a trial, evaluating the benefits and harms of cerebral oximetry combined with the SafeBoosC treatment guideline, was proven in the SafeBoosC-II trial, where 166 infants were recruited across eight European countries at eight neonatal intensive care units (32). In the SafeBoosC-III trial, a total number of 1601 newborns were randomised, with an average of 1.8 newborns randomised per day (safeboosc.eu). The results of SafeBoosC-III are published in New England Journal of Medicine (29).

During the conduct of SafeBoosC-III, the SafeBoosC consortium has been expanded and now includes neonatal intensive care units from more than 70 hospitals in 18 countries across the world, all recruited infants into the SafeBoosC-III trial (33). In these hospitals, admission records

indicate that the number of potential participants in SafeBoosC-III is larger than for the current trial. Inclusion of new neonatal intensive care units after the common start date of SafeBoosC-IIIv, will be done ad hoc, considering expected contributions and time remaining.

5 Interventions

5.1 Experimental group

The experimental group will receive cerebral oximetry added to usual care, if possible, before or as soon as possible and within six hours after invasive mechanical ventilation has been initiated and continuing until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Cerebral oximetry will be used to modify clinical care according to the SafeBoosC treatment guideline (see section 8.1 treatment based on near-infrared spectroscopy monitoring) to minimise cerebral hypoxia.

5.1.1 Monitoring by cerebral oximetry

Cerebral hypoxia will be defined as a value below 55% by the INVOS adult sensor or the corresponding value with another oximeter or sensor, as calibrated in the blood-lipid phantom (34, 35). Decisions on change of clinical management will be based on the SafeBoosC treatment guideline in combination with other clinical information.

Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. If the newborn is cared for outside the neonatal unit at any time, e.g. during surgery, cerebral oximetry may or may not be used, as decided by the responsible physician.

6 Devices

Any oximeter and sensor combination that is approved for clinical use in newborns, and which has been calibrated in the blood-lipid phantom, may be used (36).

6.1 Treatment based on adding cerebral oximetry to usual care

The SafeBoosC treatment guideline recommending adjustments of respiratory and cardiovascular support will be used to keep cerebral oxygenation above the sensor-specific hypoxic threshold as measured by the oximeter. The SafeBoosC treatment guideline is detailed in **Appendix A** and will be used in all centres. Clinical staff will be offered web-based information and training prior to caring for trial participants. The principal investigator at each neonatal intensive care unit is responsible for listing relevant clinical staff, that are expected to

use the web-based information and training, as well as providing trial information, supervision, and support.

6.1.1 Usual care

Usual care offered to newborns in the control group (see below) will be offered equally in the experimental group (e.g. antibiotics, nutrition, etc.). There will be no attempt to standardise 'usual care' among centres.

6.2 Control group

The control group will receive invasive mechanical ventilation without access to cerebral oximetry (usual care). If the newborn is cared for outside the neonatal unit at any time, e.g. during surgery, cerebral oximetry may or may not be used, as decided by the responsible physician there.

6.3 Concomitant medication/treatment

There is no specified 'per-protocol' concomitant medication or treatment. The treatment options listed in the SafeBoosC treatment guideline, is per choice of the treating physician and the treating team, as based on a comprehensive evaluation of the clinical situation of the individual newborn and local protocols and guidelines.

7 Outcomes

7.1 Outcomes for step one

7.1.1 Primary outcome for step one

- Hospital-free days within 90 days of randomisation.

7.1.2 Secondary outcomes for step one

- One or more Serious Adverse Events within 90 days of randomisation (**Appendix B**), i.e. one or more of the following:
    - Death from any cause
    - Bronchopulmonary dysplasia (BPD)
    - Any brain injury diagnosed by imaging

- Seizures treated with antiepileptic medicine
- Haemodynamic insufficiency that needs cardiovascular support
- Spontaneous bowel perforation or necrotising enterocolitis (NEC) Bells grade 2 or more
- Nosocomial infection
- Extra Corporal Membrane Oxygenation (ECMO)
- Renal replacement therapy

- Invasive mechanical ventilation-free days within 90 days of randomisation.

7.1.3 Exploratory outcomes for step one

- Late-onset sepsis
- Invasive mechanical ventilation-related infection

7.2 Outcomes for step two

7.2.1 Primary outcomes for step two

There will be two co-primary outcomes for step two, a composite dichotomised outcome and a continuous outcome:

A composite of death from any cause or moderate to severe neurodevelopmental disability at two years of corrected age. Moderate to severe neurodevelopmental disability will be defined as one or more of the following

- cerebral palsy with Global Motor Function Classification System level 2 or higher;
- a PARCA-R non-verbal cognitive function score below -2 standard deviations (SD);
- hearing loss corrected with aids or worse; or
- vision impairment defined as moderately reduced vision of one eye, or only being able to perceive light or light reflecting objects; or blind in one eye with good vision in the contralateral eye.

Parental questionnaires completed between 18-30 months' corrected age as well as available data from at least 12 months' corrected age from clinical records, including standardised neurodevelopmental assessments, will be used to assess mortality and neurodevelopment.

- Non-verbal cognitive score of PARCA-R, a parental questionnaire, at two years of corrected age.

7.2.2 Exploratory outcomes for step two

- Cerebral palsy, defined as Global Motor Function Classification System level 2 or above, at two years of corrected age.
- Sensory deficit, defined as any degree of vision or hearing impairment, at two years of corrected age.
- Mortality at two years of corrected age.
- Use of medication during the last two months, at two years of corrected age.

7.3 Outcome assessment tools

7.3.1 Outcome assessment tools for step one

All outcomes for step one will be assessed at 90 days of randomisation. Data will be collected from clinical records, and parents will be contacted (e.g. by phone or email). A Standard Operating Procedure for assessment of the primary outcome will be developed. The primary outcome will be assessed by a blinded investigator. The principal investigator from each centre must develop a local blinding procedure describing how blinding is achieved. Before the initiation of randomisation in each centre, the local blinding procedure must be approved by the trial manager. To support the principal investigators in this work, a Standard Operating Procedure with suggestions for blinding procedure will be developed.

7.3.2 Outcome assessment tool for step two

All primary outcomes for step two, as well as all exploratory outcomes evaluated at two years of corrected age, will be assessed by an online parental questionnaire. Parents of included newborns will be invited to complete the questionnaire one month before the newborn reaches two years of corrected age. A digital solution will be built for parents to fill out the questionnaires. Data can also be obtained by other means, i.e. consultations in person or by phone. If it is not possible to obtain data from the parents, the local blinded assessor will review the participants' clinical records and complete outcome assessment, as described in **Appendix D**.

Based on the SafeBoosC-III Good Clinical Practice (GCP) data monitoring model (37), a pragmatic system of local and central data monitoring based on GCP principles will be developed and used.

7.3.2.1 PARCA-R

The Parent Report of Children's Abilities-Revised, PARCA-R, is a parent completed questionnaire that can be used to assess children's cognitive and language development at 24 months corrected age (38). The questionnaire has been used as a two-year outcome measure in

multiple clinical trials (39) and has been translated into several languages. In the SafeBoosC-IIIv trial, the parents of the participating children will be invited to complete the non-verbal part of the PARCA-R questionnaire on an online platform, used in the SafeBoosC-III follow up study (to be published) and modified for the SafeBoosC-IIIv trial. The PARCA-R questionnaire must be completed between 23,5 and 27,5 months of corrected age. The non-verbal part of the PARCA-R questionnaire consists of 34 forced-choice items, zero or one, from which a total score is derived.

8 Data collection and trial assessment schedule

8.1 Collection of trial data

8.1.1 Collection of trial data in step one

Trial data will be collected using an electronic case report form (eCRF) as the primary data entry point. The eCRF will be designed in collaboration between the trial manager, data manager at Copenhagen Trial Unit and the coordinating investigator.

The assessment of the primary outcome is based on a review of clinical records and contact with the parents. The assessment of the primary outcome must be performed by a blinded assessor. We suggest the following to ensure a blinded assessment:

- Review of clinical records: A colleague, unaware of group allocation, will be presented to the infant's clinical records to assess the number of hospital-free days from randomisation until discharge/last note in the available clinical records. Prior to the assessment, the principal investigator will identify any records that could reveal group allocation and ensure this information is not presented to the blinded colleague. Alternatively, the principal investigator could print the clinical records, exclude information that reveals group allocation, and let the blinded assessor review the remaining records in print.
- Contact with parents: After reviewing the clinical records, the blinded colleague must contact the infant's parents (e.g. by phone or email) to ask if the child has been at the hospital since the date of first discharge. If the parents report that the infant has been at a hospital since the date of first discharge, the parents must report the number of days in hospital to the blinded colleague.

Based on the described assessment, the blinded colleague will determine the number of hospital-free days within 90 days from randomisation and add it to a primary outcome log. The principal investigator may transfer the data from the primary outcome log to the eCRF, since there is no outcome assessment involved in this process. A Standard Operating Procedure will be developed for assessment of the primary outcome. The investigator may choose another method for blinded

assessment of the primary outcome. However, the chosen method must be approved by the trial manager on behalf of the Steering Committee. The investigator must report and describe the chosen method to the trial manager at caroline.kamp@ctu.dk before enrolment of participants.

8.1.2 Collection of trial data in step two

Trial data will be collected using an electronic case report form (eCRF) as the primary data entry point. The eCRF will be designed in collaboration between the trial manager, data manager at Copenhagen Trial Unit and the coordinating investigator.

8.1.3 Collection of additional data

We will obtain data on participant characteristics to compare the two groups. These include sociodemographic data and clinical, treatment, and monitoring characteristics (**Appendix C**). Additional details will be provided in a Standard Operating Procedure available on safeboosc.eu.

8.2 Trial assessment schedule

When a newborn has been enrolled in the trial, this must be documented in the newborn's clinical records. The physician enrolling the participant in the trial must also be responsible for prescribing cerebral oximetry monitoring, if the participant is randomised to the experimental group. There will be three time points for eCRF data entry: 1) consent/randomisation; 2) end of monitoring, and 3) 90 days after randomisation. The data entry system, OpenClinica, will send a reminder to the principal investigators 90 days after randomisation. If funding is obtained for step two, data will be entered for parent-reported outcomes at two years of age. If there is no contact with the parents, or if they do not return the questionnaire, the local principal investigator will be asked for supplementary data (as defined in **Appendix D**) from the newborn's clinical records and requested to provide an informal assessment of the primary outcomes.

9 Assessment of Safety

9.1 Adverse events and reactions

9.1.1 Definitions

Adverse Event (AE): Any undesirable medical event occurring to a participant during a clinical trial, whether or not considered related to the trial intervention.

Adverse Reaction (AR): Any adverse event related to the trial intervention.

Serious Adverse Event (SAE): Any adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity (40, 41). The predefined individual Serious Adverse Events are listed under "8.2 Secondary outcomes".

Serious Adverse Reaction (SAR): any adverse reaction to the experimental intervention that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity (41): including:

- Physical mishaps associated with managing the oximeter and sensors
    - Severe skin damage
    - Critical displacement of endotracheal tubes caused by cerebral oximetry monitoring
    - Critical displacement of endovascular lines caused by cerebral oximetry monitoring
- Clinical mismanagement based on data from the cerebral oxygenation monitoring
    - Interventions aiming at improving respiratory status
    - Interventions aiming at improving cardiovascular status
    - Interventions aiming at improving oxygen transport

9.1.2 Reporting of adverse events and reactions

Serious Adverse Reactions and Serious Adverse Events will not be reported separately, and expedited reporting will not be used.

9.1.3 Justification for recording and reporting

The patient population of newborns in need of invasive mechanical intervention is a seriously ill group. Both intervention groups are expected to have a high proportion of adverse events, the intervention is already in widespread clinical use, and the aim of this trial is to estimate any net benefit of harm at a level of statistical significance. It is therefore not feasible, nor meaningful, to record and report all adverse events. Therefore, predefined Serious Adverse Reactions and Serious Adverse Events are described in the protocol.

9.1.4 Timing for recording and reporting

Expedited reporting will not be used. The centre investigators will report the Serious Adverse Reactions through the eCRF at end of monitoring. Serious Adverse Events will be reported through the eCRF at 90 days after randomisation. The sponsor will inform all investigators in the case of unexpected patterns of Serious Adverse Reactions and Serious Adverse Events, as

evaluated by individual investigator reporting, central data monitoring, and interim analyses. Ethics committees will be informed as required.

9.2 Cerebral oximetry monitoring device

The devices used are approved for clinical use in newborns and will be used according to the user manuals provided by the manufacturers. Furthermore, all clinical staff will be offered web-based training that covers the principles of cerebral oximetry, practical application, as well as pathophysiology, and relevant interventions in the case of low cerebral oxygenation.

9.3 Data Monitoring and Safety Committee

A Data Monitoring and Safety Committee (DMSC) will be established to monitor mortality and neonatal morbidities at 90 days of life, including Serious Adverse Reactions and Serious Adverse Events. The charter for the DMSC will be written prior to inclusion of participants and prior to any analysis. The first pre-planned interim analysis will be conducted after one-third of the participants have reached 90 days after randomisation (537 participants). Additional interim analyses will be decided by the DMSC. The DMSC will be given access to data by randomisation group. The DMSC may advice the trial Steering Committee to stop the trial early if there is risk of important negative effects of the intervention. The trial will not be stopped early because of futility. Lan-DeMets boundaries will be used at each interim analysis to assess if the thresholds for statistical significance are crossed and if the trial should be stopped early because of evidence of benefit or harm (42).

9.4 Suspension or premature termination of the trial

The Steering Committee decides about trial discontinuation. If the Steering Committee terminates or suspends the trial, the relevant ethical committees will be provided with a detailed written explanation of the termination or suspension. The Steering Committee can, upon completion of the analysis of the reason(s) for a suspension, decide to lift the suspension when any necessary corrective actions have been implemented. The investigators and ethical committees will be notified and provided with the relevant data supporting the decision. Breaking of blinding for clinicians and parents will not be relevant in this trial, since group allocation is visible for them.

10 Ethical considerations

Due to the pathophysiology of newborns, the research question can only be answered in this critical ill population.

To obtain evidence-based knowledge on the benefit and harms of cerebral monitoring using cerebral oximetry as part of clinical management of invasive mechanical ventilation in newborns, a large-scale randomised clinical trial is needed. The SafeBoosC phase II trial served as a feasibility trial for the large SafeBoosC-III trial that is now close to completion. These trials test the use of cerebral oximetry in extremely preterm infants during the cardio-respiratory transition from intra-uterine to extra-uterine life in the first three days of life. They provide a basis for the new SafeBoosC-IIIv trial that tests cerebral oximetry as an element of intensive care during invasive mechanical ventilation at any time during the neonatal period. At the present time, there is clinical equipoise, which means that there is genuine uncertainty over whether the cerebral oximeter and subsequent treatments will be beneficial or may even be harmful to study participants. There are no data to support substantially more risk or discomfort as compared with no intervention. All interventions proposed in the SafeBoosC treatment guideline are also commonly used in this patient group.

'Usual care', i.e. treatment according to each hospital's standard procedures will be given to the control group but without access to cerebral oximetry. Also, this will be the care given to any participant that is withdrawn, and newborns who are not included in the trial.

No clinical site will start randomisation before their eligibility has been confirmed, and the protocol has been approved by the relevant ethics committee. Any amendments to the protocol will be decided by the Steering Committee, and subject to ethical review before implemented. Written informed consent will be obtained prior to randomisation of any participant. However, the local neonatal intensive care units have the possibility to apply for the use of 'deferred consent', or 'opt-out' when obtaining approval of the protocol at their ethical committee. Parents can withdraw their consent for participation at any time. The trial will be conducted in compliance with the guidelines of the Declaration of Helsinki in its latest form and following the International Conference on Harmonisation Good Clinical Practice principles (43) and the applicable European Union regulations and directives. The trial protocol will be registered at www.clinicaltrials.gov prior to participant enrolment, and, after completion of the trial, summary data will be uploaded.

10.1 Informed consent procedure for prior consent

Informed consent is required from one or both parents, according to local regulations. The investigator/investigator's delegate (qualified physician or nurse connected to the trial) will make contact, and parents will be informed of the trial and given the parent information sheet **(**a template in English will be provided from Copenhagen Trial Unit for adaptation to local requirement**)** for the trial. The information consultation will be held in an undisturbed setting as far as possible. The parents will be given time to consider as far as possible, given the need to begin the intervention as fast as possible after intubation and to ask questions before a written

informed consent (an English template will be available**)** will be obtained. Parents will be given a signed copy of the informed consent.

10.2 Deferred informed consent and opt-out

Due to the nature of the population and the sudden need for invasive mechanical ventilation, it may be difficult to obtain prior informed consent from the parents in satisfactory way. Therefore, we allow the principal investigators at each neonatal intensive care unit, to seek approval for deferred informed consent and/or opt-out (44).

10.3 Risk of complications for participants

The following procedure will be implemented to prevent and/or minimise risk of complication for participants.

Related to devices
Correct reading of the monitor (since false readings may lead to wrong treatments) is critical. All clinical staff will be offered and expected to complete web-based training, and the investigators will train the local staff as appropriate, and trained staff will closely supervise all participants during the intervention. To minimise skin irritation related to the device, the care for sensor should follow the user manual.

Related to application of the SafeBoosC treatment guideline
The SafeBoosC treatment guideline used in this trial has been tested in two trials (27, 44). The SafeBoosC treatment guideline is in harmony with current national clinical practices. All staff caring for trial participants will be offered the web-based training programme.

10.4 Benefit for participant

The participants in both groups will receive careful attention from qualified physicians and hospital staff during the trial.

11 Statistical plan and data analysis

11.1 Sample size estimation

11.1.1 Sample size estimation for step one

A sample size calculation on the primary outcome (hospital-free days) shows that to test a relative risk reduction of death of 5% and an absolute increase of 3 days in the estimate of hospital-free days of the surviving participants (considered clinically relevant) with an alpha of

0.05 and a power of 90% using the van Elteren test, we would need to include 1,610 participants (**Appendix E**).

11.1.2 Power estimations for step one

Based on data from Statistics Denmark and from Rigshospitalet (45, 46), we assume 20% of the newborns receiving invasive mechanical ventilation will experience one or more serious adverse events within 90 days of randomisation. With a relative risk reduction of 30% in the experimental group, we will be able to detect this difference between the experimental and control group with 89% power at a 5% significance level.

For invasive mechanical ventilation-free days, we defined a clinically relevant relative risk reduction of 5% and an absolute increase of 3 days in the estimate. Based on an alpha of 0.05 using the van Elteren test, we would have a power of 100% when including 1,610 participants.

11.1.3 Sample size estimation for step two

A sample size calculation on the dichotomised, composite primary outcome shows that to test a reduction in death or moderate to severe neurodevelopment disability from 20% to 16% between the experimental and control group, at an alpha-level of 2.5% and a power of 80%, a total of 1,500 participants in each group, i.e. a total of 3,000, is needed. This corresponds to a relative risk reduction of 20%.

11.1.4 Power estimations for step two

A power analysis for the continuous primary outcome, i.e. non-verbal cognitive score of PARCA-R, shows that, with a sample of 1,500 in each group and an expected rate of death of 8%, and a standard deviation of the PARCA score of 18 points, the power will be more than 98% to detect a difference of 3 points, at an alpha of 2.5%.

11.2 Data analysis and statistical methods

A fully detailed statistical analysis plan will be developed and published before analyses are performed. General principles are outlined below.

The primary analysis of all outcomes will be based on the intention-to-treat population, and all data will be used, i.e. data from the clinical records and from contact with parents.

Mixed-effect logistic regression and mixed-effect linear regression will be used to analyse the dichotomous and continuous co-primary outcomes, respectively. We will for all dichotomous outcomes calculate relative risks using the NLCOM STATA command. Data from all participating centres will be used in the primary analysis of all outcomes. In the regression models, ‘centre’ will be included as a random effect, while ‘gestational age below or above 34

weeks of postmenstrual age', 'group allocation', and 'surgery' will be included as fixed effects. Multiples will be treated as independent observations and will, as mentioned, be randomised independently (47). We will use a five-step procedure to assess if the thresholds for statistical and clinical significance are crossed (42). Our primary conclusions will be based on the primary outcome, and all remaining results will be considered hypothesis generating. Hence, we will consider a p-value of less than 0.05 as statistically significant.

11.2.1 Analysis of outcomes

Dichotomous outcomes will be summarised as numbers, percentages, risk ratios, and 95% confidence intervals. Continuous outcomes will be summarised by mean and standard deviation if normally distributed or by median and interquartile range if non-normally distributed.

11.2.2 Assessment of components of the dichotomised primary outcome for step two

In step two, we will secondly assess each component of the dichotomised primary outcome, i.e. death and moderate to severe neurodevelopmental disability.

11.2.3 Threshold for significance

The thresholds for significance for the primary outcomes, will be assessed according to the 5-point procedure suggested by Jakobsen et al. (42, 48).

11.2.4 Missing outcomes

Missing data will be handled per the recommendation by Jakobsen et al. (49) In short, we will consider using multiple imputation and present best-worst and worst-best case scenarios, if it is not valid to ignore missing data (49). Best-worst and worst-best case scenarios assess the potential range of impact of the missing data for the trial results (49). In the 'best-worst' case scenario, it is assumed that all participants lost to follow-up in the experimental group have had a beneficial outcome, and all those with missing outcomes in the control group have had a harmful outcome (49). Conversely, in the 'worst-best' case scenario, it is assumed that all participants who were lost to follow-up in the experimental group have had a harmful outcome, and that all those lost to follow-up in the control group have had a beneficial outcome (50). We will consider using multiple imputation based on a flow chart (49).

12 Data management plan

12.1 Data handling and archiving

All participant data are protected in accordance with the EU General Data Protection Regulation (GDPR) regulations. The data flow is outlined in **Appendix C**.

Copenhagen Trial Unit will provide central, web-based data entry (in the eCRF) using OpenClinica, an open source data management environment that was also used for SafeBoosC-II and III. Data will be managed and stored after approval by the Knowledge Centre on Data Protection Compliance, the Capital Region of Denmark. Only neonatal intensive care unit numbers and study numbers will be used to identify participants (i.e. the data kept at Copenhagen Trial Unit are pseudonymised), while lists of study numbers and personal identifying information (e.g. to allow local monitoring, data cleansing, and later follow-up) will be kept at the hospitals responsible for clinical care.

The dataset will be kept at the Capital Region of Denmark for 20 years. Six months after the acceptance of the publication that presents the primary outcome, the dataset can be shared with other researchers. Before sharing, subject study numbers, will be removed, neonatal intensive care unit numbers will be replaced, gender and twin status removed, birth weight and gestational age recoded into binary variables to minimise the risk of reidentification. Use by other researchers will depend on the permission of the trial Steering Committee. The investigators permit trial-related monitoring, audits, and regulatory inspections by providing direct access to the source data and other relevant documents.

13 Quality assurance

The trial will be conducted in compliance with this protocol across all centres. Detailed instructions and Standard Operating Procedures will be developed for specific tasks, as needed. Any major or safety related deviations will be recorded, analysed and reported to the research ethics committees within seven workdays. If an investigator refuses to comply with the protocol, he/she will be disqualified.

13.1 Eligibility

13.1.1 Centres

Criteria for a centre can take part in the SafeBoosC-IIIv trial

1. Can include at least 10 newborns per year
2. The centre has implemented or will implement the application of cerebral oximetry at a high level of clinical competence at all times during the trial.

3. The responsible physician and clinical staff are in equipoise as regards to the clinical value of cerebral oximetry in newborns on invasive mechanical ventilation.

13.1.2 Trial personnel

Criteria for individuals who will perform the interventions

We will offer web-based training, where trial personnel will be invited to participate. It will cover the protocol, cerebral oximetry (the basic principles and device operation) and the SafeBoosC treatment guideline (the possible clinical interventions and the rationale of the SafeBoosC treatment guideline). If the principal investigator finds it more feasible, training in groups or for individuals may be arranged, based on the material from the web-based training. All trial personnel must document their training on the delegation log and sign it, before caring for trial participants.

13.2 Monitoring

13.2.1 Central monitoring

Central monitoring will consist of central daily check of recruitment to the trial, and the quality, completeness, and timeliness of data entry in the eCRF by the trial manager, the coordinating investigator, and Copenhagen Trial Unit. Statistics of the central monitoring will be published on the trial website. In case of problems, the national coordinators or principal investigators as relevant, will be contacted for verification/correction. The central monitoring will be conducted as described by Harboe Olsen et al. (37).

13.2.2 Local monitoring

The trial will be monitored based on the International Conference on Harmonization Good Clinical Practice principles, and a detailed monitoring plan will be developed. The following will be monitored locally:

- All participants for existence of clinical records, existence of documented informed consent, and entry of trial participation in clinical records. Data for group allocation, gestational age, survival or death at 90 after randomisation, hospital-free days, and delegation logs will be entered by the local investigator and source checks will be done by an independent monitor.

13.3 Device quality control

Each centre is responsible for adhering to the quality control measures described in the oximeter manufacturer's user's guideline.

14 Trial timeframe

Trial stages	Time frame
Protocol development	February 2024 – July 2024
Protocol finalised	August 2024
Centre selection	Ongoing
Recruitment phase	To be decided
Assessment phase	To be decided
Final analysis	To be decided
Publication	To be decided

15 Legal aspects

15.1 Finance

The sponsor/coordinating investigator, Professor Janus Christian Jakobsen, representing the Capital Region, Denmark, is the initiator of the SafeBoosC-IIIv project. He has no financial interest in the results of the trial, nor in the cerebral oximetry-devices. We have received funding from the Independent Research Fund Denmark to cover central trial costs for step one. We will seek additional central funding, including funding from industry sponsors, but such sources will not get any influence on the methodology, data, analysis, reporting, or conclusions of the trial. Furthermore, any participating centre can seek local/national support from all sources, including dealers of devices, as long such sources will not get any influence on the methodology, data, analysis, reporting, or conclusions of the trial. No financial compensation is foreseen for hospitals participating in this trial.

15.2 Conflict of interest

The authors declare that they have no competing interest.

15.3 Participant insurance

Participants will, if needed, be insured in accordance with existing legislation in their respective countries. Individual neonatal intensive care units are obliged to finance the participants' insurances if relevant.

15.4 Publication plan

The trial will be registered on www.clinicaltrials.gov prior to the randomisation of the first participant. Summary data of the primary outcomes will be uploaded after statistical analyses are completed, if acceptable to the journal to which the manuscript is submitted. Attempts will be sought to publish all results, positive, neutral, as well as negative, in peer-reviewed international journals. Results of step one will be published even if funding for step two is not obtained.

Substudies with results potentially affecting equipoise regarding the value of cerebral oximetry, shall not be published before the main publication of SafeBoosC-IIIv.

15.5 Authorships

Authorship will be determined according to the International Committee of Medical Journal Editors.

- An additional requirement is one author per centre completing (randomise and complete data entry) at least 10 participants per year. The Steering Committee may allow more than one author from neonatal intensive care units that contribute with more participants.
- The principal investigators, the Steering Committee, and members from the SafeBoosC Copenhagen project team that are not principal investigators or Steering Committee members, will be stated as byline authors
- If there is a need for a blinded assessor for the two-year follow-up due to missing parent-reported outcomes, these will be stated as collaborators in the SafeBoosC-IIIv consortium

15.6 Statements of compliance

The randomised clinical trial will be conducted in accordance with this protocol, its Standard Operating Procedures and based on Good Clinical Practice principles.

16 Appendix

16.1 Appendix A: Treatment guideline

The SafeBoosC treatment guideline

Assessment of cerebral oxygen saturation
Regional cerebral tissue oxygen saturation (rStO2) is a composite measure of tissue oxygen saturation across arterial, capillary and venous beds and reflects a balance between cerebral oxygen delivery (CDO2) and cerebral metabolic rate (CMRO2). In preterm infants, the CMRO2 is unlikely to vary much and a change in rStO2 largely reflects changes in CDO2. The factors which influence CDO2 are arterial oxygen saturation (SaO2), haemoglobin concentration and cerebral blood flow (CBF).

Recommendation for clinical interventions
The threshold for intervention depends on the oximeter. If StO2 is predominantly below the hypoxic threshold over a 10-minute period or drops acutely and markedly under the threshold, the sensor should be inspected for any potential displacement, and possibly be repositioned. If this does not solve the problem, a decision regarding intervention (modification of cardio-respiratory support) should be made (identified in '•') as listed below and StO2 reassessed 30 to 60 minutes after the intervention. Generally, only one intervention should be chosen at a time. All the interventions proposed here are commonly used in this patient group.

For each intervention, the level of evidence (I-III) and strength of recommendation (A-E) are given (defined in Tables 1 and 2). For further explanation, see below.

Rationale/aim of interventions: A low rStO2 reflects a low CDO2. The interventions should be directed to increasing CBF, blood haemoglobin concentration, or SaO2.

<u>Assess cardiovascular status:</u>
Blood pressure below the normal range or low, even in the normal range, consider:

- Vasopressor-inotropes (I/B) (51, 52)
- Fluid bolus (normal saline) (I/C)(53, 54)
- Decrease mean airway pressure on ventilator or CPAP (III/B)(55-58)

Poor systemic circulation, consider if:
Echocardiography shows low cardiac output and/or low SVC flow, consider:

- Inotropes (I/B)(17, 54, 59-62)
- Fluid bolus (normal saline) (I/C) (53, 54)
- Decrease mean airway pressure (III/B) (55-58)

- Reduce vasopressor (III/ B) (63)

Echocardiography not available but has at least 2 of the following signs:
Lactate > 3.5 mmol/l
Capillary Refill Time > 3 seconds
Urine output < 1 ml/kg/hour consider:

- Inotropes (I/B) (17, 54, 59-62)
- Fluid bolus (normal saline) (I/C)(53, 54)
- Decrease mean airway pressure (III/B) (55-57)
- Reduce vasopressor (III/ B) (63)

Patent ductus arteriosus, consider:

- Medical treatment (II-2/B) (56, 58, 64, 65)

<u>Assess oxygen transport:</u>
Blood haemoglobin concentration below the normal range or low, even in the normal range, consider:

- Red blood cell transfusion (I/B)(66-68)

<u>Assess respiratory status:</u>
SaO2 below the normal range or low, even in normal range, consider:

- Increase FiO2 (II-1/A)(69)(ATTENTION: be careful not to exceed the upper target threshold of SpO2)
- Increase mean airway pressure (III/B) (55, 70, 71)

PCO2 below the normal range or low, even in normal range, consider:

- Decrease minute ventilation - (II/A) (66, 72-74)

Level of evidence and recommendation of intervention
The level of evidence (Table 1) and recommendation for a given intervention (in brackets and Table 2) were graded according to the U.S. Preventive Services Task Force system (75)

Table 1: Hierarchy of research design and level of evidence

Level of evidence	Type of study
I	Evidence obtained from at least one properly randomized controlled trial
II-1	Evidence obtained from well-designed controlled trials without randomization
II-2	Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or research group
II-3	Evidence obtained from multiple time series with or without intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence
III	Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees

Table 2: Recommendation grid

	Net benefit			
Quality of evidence	substantial	moderate	small	zero/negative
Good	A	B	C	D
Fair	B	B	C	D
Poor	E	E	E	E
Standard recommendation language	A= Strongly recommended (good evidence that the intervention improves important health outcomes and benefits substantially outweigh harms). B= Recommended (at least fair evidence that the intervention improves important health outcomes and benefits substantially outweigh harms). C= No recommendation for or against routine provision of the intervention (fair evidence that the service can improve health outcomes but the balance of the benefits and harms is too close to justify a general recommendation). D= Recommends against routinely providing the intervention (at least fair evidence that the service is ineffective or that harms outweigh benefits). E= Insufficient to recommend for or against routinely providing the intervention (evidence that the intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined).			

16.2 Appendix B: Definitions of serious adverse events

One or more serious adverse events within 90 days of randomisation: death from any cause, bronchopulmonary dysplasia, any brain injury diagnosed by imaging (if both ultrasound and MRI are available, MRI will be prioritized), seizures treated with antiepileptic medicine, hemodynamic insufficiency that needs cardiovascular support, spontaneous bowel perforation or necrotizing enterocolitis defined as Bell's grade 2 or more, extracorporeal membrane oxygenation treatment, renal replacement therapy, and nosocomial infection.

The diagnoses of any of the serious adverse events will be made by the outcome assessor using clinical records, however, the following definitions are recommended.

The following **neonatal outcomes** expressed as the **grades outlined below or above** (adapted from: **E**uropean **N**ewborn **S**tudy: **E**arly **M**arkers for a **B**etter **L**ife-ENSEMBLE; International Neonatal Consortium (doi: 10.1136/archdischild-2019-317399); European Standards of Care for Newborn Care (EFCNI))**.**

Bronchopulmonary dysplasia (grade 2):

a. Supplemental oxygen at 28 days AND need for 22-30% oxygen at 36 weeks PMA in infants born <32 weeks' gestation; need for 22-30% oxygen by 56 days postnatal age in infants born >32 weeks' gestation; need for 22-30% oxygen at discharge. Note: For conversion of oxygen administered by different modalities to FiO2, see http://nicutools.org/MediCalcs/ActualO2.php3.

Brain injury documented either by cranial ultrasound (CU), magnetic resonance imaging (MRI), or computed tomography (CT):

a. Peri-intraventricular hemorrhage (grade 2 or more): Hemorrhage occupying less than 50% of the ventricle volume.
b. Periventricular haemorrhagic (venous) infarction.
c. Post-haemorrhagic ventricular dilatation: ventricular dilatation with ventricular index > 4mm above the 97th percentile or anterior horn with > 6 mm or need of CSF removal (drain, shunt, reservoir, lumbal puncture).
d. Periventricular leukomalacia (grade 2) (CUs diagnosis): Transient periventricular echodensities evolving into small, localized frontal-parietal cysts or persistent diffuse echodensities.
e. Extensive punctate white matter injury (MRI diagnosis).
f. Perinatal ischemic stroke.
g. Acute HI brain damage:
    i. (CU diagnosis): i) brain swelling; ii) bilateral-symmetric basal ganglia-thalamic injury or focal (asymmetric) hyperechoic areas; iii) laminar cortical necrosis; iv) periventricular and/or subcortical white matter injury
    ii. (MRI diagnosis): i) Central and/or peri-rolandic gray matter damage; ii) Hypoxic-ischemic injury in watershead areas.
h. Cerebellar injury (ischemic-haemorrhagic) involving vermis or >1/3 of hemisphere.
i. Big extra-axial bleeding or parenchymal bleeding/contusion with/without midline shift.

j. Other: imaging findings related to CNS acquired infection.

Neonatal seizures that need for treatment

a. Neonatal epileptic seizure (grade 2): electroencephalogram (EEG)-proven seizures that are controlled with one anti-seizure drug (no recurrence within three days after treatment).
b. Neonatal Convulsions (grade 3): Suspected seizures (no EEG) uncontrolled with one anti-seizure drug (recurrence within three days after treatment or requiring two or more anti-seizure drugs).

Hemodynamic insufficiency

a. Persistent hypotension (grade 3): hypotension affecting perfusion; requiring major care change (e.g., vaso-active drugs or hydrocortisone).
b. Clinical signs of compromised perfusion regardless blood pressure (raised serum lactate, poor urine output, central-to-peripheral temperature gap, prolonged skin refill-time, echocardiographic parameters) requiring major care change (e.g., vaso-active drugs or hydrocortisone).

Bowel AE

a. Neonatal spontaneous intestinal perforation (grade 3): presence of spontaneous intestinal perforation (SIP), non-urgent medical stabilization and surgical intervention indicated.
b. NEC (Bell's stage 2): confirmed NEC with lack of bowel sounds, pain, and tenderness in the abdomen, low or no intestinal movement, presence of gasfilled spaces in the intestinal walls, including stage 1 clinical signs (lethargy, vomiting, bloody stools abdominal bloating, slow heart rate and unstable temperature).

Renal replacement therapy

a. Infants receiving any of the following therapies: peritoneal dialysis, hemodialysis, or hemofiltration.

Nosocomial infection

a. Late-onset sepsis: Defined as antibiotics prescribed after 72 hours and given for 5 days or more.
b. Invasive mechanical ventilation (endotracheal or tracheostomy)-related infection

16.3 Appendix C: Timing of data collection

	Before randomisation	End of monitoring	90 days after randomisation	2 years of corrected age
Eligibility criteria + stratification variables	x			
Sociodemographic data	x	x		
Treatment + monitoring data		x		
Serious adverse reactions		x		
Hospital-free days			x	
Serious adverse events			x	
Invasive mechanical ventilation-free days			x	
Clinical status			x	
Parental questionnaires				x

16.4 Appendix D: Prioritisation of data for the co-primary outcome moderate-or-severe NDD for step two



NDD = moderate-or-severe neurodevelopmental disability = positive findings for at least one of the four components or NDD based on an informal blinded assessment of all available information
No NDD = no moderate-or-severe neurodevelopmental disability = no positive findings in any of the four components and no NDD based on an informal blinded assessment of all available information
Unclassifiable = if one or more components are unknown and none are positive and there is no informal assessment.

16.5 Appendix E: Sample size

Simulation of sample size for SafeBoosC-IIIv

Markus Harboe Olsen

08 december 2023

Contents

Introduction

The SafeBoosC-IIIv is a randomised clinical trial designed as superiority trial to asses days alive and out-of-hospital. We chose to use statistical simulations to estimate the required sample size to achieve a power of 90%. This, using an alpha of 0.05.

Sample data

To carry out these simulations, we used data from the danish national registry. Between 2001 and 2018, 1,392 children were born who were in mechanical ventilator and did not have any heart defects. Pseudonymised data were assessed for days alive and out-of-hospital. Of those, 140 (10.1%) dies within 90 days.

The data below is used for the simulations:

DAOH	All	Mortality	Alive	Dead
	n	n (%)	mean (SD)	mean (SD)
0	169	129 (76.3%)	-	.
1-10	33	9 (27.3%)	5.5 (2.8)	4.8 (2.8)

DAOH	All	Mortality	Alive	Dead
11-20	64	0 (0%)	16.2 (2.6)	-
21-30	52	0 (0%)	25.1 (2.9)	-
31-40	78	0 (0%)	35.8 (2.9)	-
41-50	88	0 (0%)	45.6 (3.1)	-
51-60	101	2 (1.4%)	55.6 (2.9)	-
61-70	173	0 (0%)	66.2 (2.7)	-
71-80	285	0 (0%)	75.8 (2.9)	-
81-89	344	0 (0%)	84.9 (2.4)	-
90	3	0 (0%)	-	-

Simulation procedure

For each trial, the above-shown table is simulated so the two missing participants who died in the 51-60 category is simulated to have the same distribution as the alive participants in the same category. Each participant is first classified as alive or dead, depending on the defined risk. The baseline risk is 10.1%. Next, the participant is assigned to one of the above defined groups based on the probability from the number of participants in the simulated assignment table. Finally, the participants specific DAOH is then assigned based on the mean and SD.

Here we present a graphical presentation of participants from one simulated trial with 1,392 participants without any intervention effect, stratified by alive or dead.



Planned statistical analysis

We aim to use Wilcox rank sum test to estimate median difference and 95% Hodghes-Lehmann confidence intervals. The primary analysis used for sample size calculation will be Van Elteren test. As sensitivity analyses, we will use mixed effect linear regression with site as a random effects covariate and gestational age (above or below 34 weeks) as a fixed effect covariate and also the Kryger Jensen and Lange test which was developed specifically for distributions of outcome results that show many patients with a value of zero, which would be the case for the number of days alive and out of the hospital. Here, the p-value will be used to estimate power for the different sample sizes.

Intervention effects

We proposed the intervention will have a relative risk reduction in mortality of 5%, i.e. an absolute decrease of 0.50%. This decreases the mortality from 10.06% to 9.55%. Furthermore, we propose an absolute increase of 3 days in the estimate of days out-of-hospital of the surviving participants.

Based on an alpha of 0.05, we investigate when the power of the Van Elteren analysis exceed 90%.



After inclusion of 1,610 participants the power of the analysis would reach a stable level of 90% or above.

Furthermore, we investigated the power of the sensitvity analyses when including 1,610 participants:



Statistical analysis	Estimate (95%CI)
Mixed effects linear regression	49.7 (46.6;52.8) %
Kryger Jensen Lange test	50.6 (47.5;53.7) %
Fixed-effect linear regression	48.8 (45.7;51.9) %
Wilcoxon rank sum test	92.2 (90.54;93.86) %
Van Elteren test	91.4 (89.66;93.14) %

As seen the power of the sensitivity analyses are under-powered for this exact outcome. Finally we need to ensure the Type-1 error does not exceed 5% for trial without any intervention effect.



Statistical analysis	Estimate (95%CI)
Mixed effects linear regression	4.1 (2.87;5.33) %
Kryger Jensen Lange test	4.8 (3.47;6.13) %
Fixed-effect linear regression	4.3 (3.04;5.56) %
Wilcoxon rank sum test	4.3 (3.04;5.56) %
Van Elteren test	3.7 (2.53;4.87) %

For all analyses the type-1 error is below 5%.

Power calculations

Days alive and out of mechanical ventilation

Days alive and out-of-respirator (DAOR) / mechanical ventilator is a secondary outcome. The simulations are carried out by using DAOR from 1,800 previous patients admitted to Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark:



Based on a relative risk reduction of 5% in mortality (from the previously defined 10.1%) and a minimum relevant difference of 3 days in the surviving participants, we carried 1,000 simulations from a trial including 1,610 participants.



sa	Statistical analysis
Mixed effects linear regression	35.6 (32.63;38.57) %
Kryger Jensen Lange test	99.8 (99.52;100.08) %
Fixed-effect linear regression	35.7 (32.73;38.67) %
Wilcoxon rank sum test	100 (100;100) %
Van Elteren test	100 (100;100) %

Now we investigate the type-1 error:



sa	Statistical analysis
Mixed effects linear regression	5 (3.65;6.35) %
Kryger Jensen Lange test	5 (3.65;6.35) %
Fixed-effect linear regression	5.2 (3.82;6.58) %
Wilcoxon rank sum test	5.4 (4;6.8) %

sa	Statistical analysis
Van Elteren test	5.6 (4.17;7.03) %

17 References

1. Parker JC, Hernandez LA, Peevy KJ. Mechanisms of ventilator-induced lung injury. Crit Care Med. 1993;21(1):131-43.
2. Attar MA, Donn SM. Mechanisms of ventilator-induced lung injury in premature infants. Semin Neonatol. 2002;7(5):353-60.
3. Miller JD, Carlo WA. Pulmonary complications of mechanical ventilation in neonates. Clin Perinatol. 2008;35(1):273-81.
4. Stolwijk LJ, Lemmers PM, Harmsen M, Groenendaal F, de Vries LS, van der Zee DC, et al. Neurodevelopmental Outcomes After Neonatal Surgery for Major Noncardiac Anomalies. Pediatrics. 2016;137(2):e20151728.
5. Overview of mechanical ventilation in neonates [Internet]. 2021 [cited 09/08/2021]. Available from: https://www.uptodate.com/contents/overview-of-mechanical-ventilation-in-neonates?search=mechanical%20ventilation&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#references.
6. Blinder JJ, Thiagarajan R, Williams K, Nathan M, Mayer J, Kulik TJ. Duration of Mechanical Ventilation and Perioperative Care Quality After Neonatal Cardiac Operations. Ann Thorac Surg. 2017;103(6):1956-62.
7. Rolfe P, Scopesi F, Sun J, Serra G. Physiological Monitoring in the Ventilated Neonate: A Rationale. 192008. p. 413-6.
8. Martin K, Weiss SL. Initial resuscitation and management of pediatric septic shock. Minerva Pediatr. 2015;67(2):141-58.
9. Schat TE, Schurink M, van der Laan ME, Hulscher JB, Hulzebos CV, Bos AF, Kooi EM. Near-Infrared Spectroscopy to Predict the Course of Necrotizing Enterocolitis. PLoS One. 2016;11(5):e0154710.
10. Wolf M, Greisen G. Advances in near-infrared spectroscopy to study the brain of the preterm and term neonate. Clin Perinatol. 2009;36(4):807-34, vi.
11. Ostojic D, Jiang J, Isler H, Kleiser S, Karen T, Wolf M, Scholkmann F. Impact of Skull Thickness on Cerebral NIRS Oximetry in Neonates: An in silico Study. Adv Exp Med Biol. 2020;1232:33-8.
12. Watzman HM, Kurth CD, Montenegro LM, Rome J, Steven JM, Nicolson SC. Arterial and venous contributions to near-infrared cerebral oximetry. Anesthesiology. 2000;93(4):947-53.
13. Benni PB, MacLeod D, Ikeda K, Lin HM. A validation method for near-infrared spectroscopy based tissue oximeters for cerebral and somatic tissue oxygen saturation measurements. J Clin Monit Comput. 2018;32(2):269-84.
14. Kim MB, Ward DS, Cartwright CR, Kolano J, Chlebowski S, Henson LC. Estimation of jugular venous O2 saturation from cerebral oximetry or arterial O2 saturation during isocapnic hypoxia. J Clin Monit Comput. 2000;16(3):191-9.
15. Daubeney PE, Pilkington SN, Janke E, Charlton GA, Smith DC, Webber SA. Cerebral oxygenation measured by near-infrared spectroscopy: comparison with jugular bulb oximetry. Ann Thorac Surg. 1996;61(3):930-4.
16. O'Neill R, Dempsey EM, Garvey AA, Schwarz CE. Non-invasive Cardiac Output Monitoring in Neonates. Front Pediatr. 2021;8:614585-.
17. Moran M, Miletin J, Pichova K, Dempsey EM. Cerebral tissue oxygenation index and superior vena cava blood flow in the very low birth weight infant. Acta Paediatr. 2009;98(1):43-6.
18. MJ. C. The Cerebral Circulation. San Rafael (CA): Morgan & Claypool Life Sciences; 2009. Chapter 5, Control of Cerebral Blood Flow.

.
19. Greisen G. Autoregulation of cerebral blood flow in newborn babies. Early Hum Dev. 2005;81(5):423-8.
20. Bevan R, Dodge J, Nichols P, Poseno T, Vijayakumaran E, Wellman T, Bevan JA. Responsiveness of human infant cerebral arteries to sympathetic nerve stimulation and vasoactive agents. Pediatr Res. 1998;44(5):730-9.
21. Greisen G, Vannucci RC. Is periventricular leucomalacia a result of hypoxic-ischaemic injury? Hypocapnia and the preterm brain. Biol Neonate. 2001;79(3-4):194-200.
22. Rhee CJ, da Costa CS, Austin T, Brady KM, Czosnyka M, Lee JK. Neonatal cerebrovascular autoregulation. Pediatr Res. 2018;84(5):602-10.
23. Collins JA, Rudenski A, Gibson J, Howard L, O'Driscoll R. Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve. Breathe (Sheff). 2015;11(3):194-201.
24. Yıldız EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert Rev Neurother. 2017;17(5):449-59.
25. Ahearne CE, Boylan GB, Murray DM. Short and long term prognosis in perinatal asphyxia: An update. World J Clin Pediatr. 2016;5(1):67-74.
26. Dunbar M, Kirton A. Perinatal stroke: mechanisms, management, and outcomes of early cerebrovascular brain injury. Lancet Child Adolesc Health. 2018;2(9):666-76.
27. Hyttel-Sorensen S, Pellicer A, Alderliesten T, Austin T, van Bel F, Benders M, et al. Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial. BMJ. 2015;350:g7635.
28. Pichler G, Urlesberger B, Baik N, Schwaberger B, Binder-Heschl C, Avian A, et al. Cerebral oxygen saturation to guide oxygen delivery in preterm neonates for the immediate transition after birth: a 2-center randomized controlled pilot feasibility trial. J Pediatr. 2016;170:73-8.e1-4.
29. Hansen ML, Pellicer A, Hyttel-Sorensen S, Ergenekon E, Szczapa T, Hagmann C, et al. Cerebral Oximetry Monitoring in Extremely Preterm Infants. N Engl J Med. 2023;388(16):1501-11.
30. Pichler G, Goeral K, Hammerl M, Perme T, Dempsey EM, Springer L, et al. Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth (COSGOD III): multicentre randomised phase 3 clinical trial. BMJ. 2023;380:e072313.
31. Hansen ML, Hyttel-Sorensen S, Jakobsen JC, Gluud C, Kooi EMW, Mintzer J, et al. Cerebral near-infrared spectroscopy monitoring (NIRS) in children and adults: a systematic review with meta-analysis. Pediatr Res. 2022.
32. Hyttel-Sorensen S, Greisen G, Als-Nielsen B, Gluud C. Cerebral near-infrared spectroscopy monitoring for prevention of brain injury in very preterm infants. Cochrane Database Syst Rev. 2017;9(9):Cd011506.
33. group TS. Newsletter 2021 [Available from: https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/department-of-neonatology/research/SafeboosC-III/Sider/newsletters.aspx.
34. Kleiser S, Nasseri N, Andresen B, Greisen G, Wolf M. Comparison of tissue oximeters on a liquid phantom with adjustable optical properties. Biomed Opt Express. 2016;7(8):2973-92.
35. Kleiser S, Ostojic D, Andresen B, Nasseri N, Isler H, Scholkmann F, et al. Comparison of tissue oximeters on a liquid phantom with adjustable optical properties: an extension. Biomed Opt Express. 2018;9(1):86-101.

36. Hyttel-Sorensen S, Kleiser S, Wolf M, Greisen G. Calibration of a prototype NIRS oximeter against two commercial devices on a blood-lipid phantom. Biomed Opt Express. 2013;4(9):1662-72.
37. Olsen MH, Hansen ML, Safi S, Jakobsen JC, Greisen G, Gluud C. Central data monitoring in the multicentre randomised SafeBoosC-III trial - a pragmatic approach. BMC Med Res Methodol. 2021;21(1):160.
38. Blaggan S, Guy A, Boyle EM, Spata E, Manktelow BN, Wolke D, Johnson S. A parent questionnaire for developmental screening in infants born late and moderately preterm. Pediatrics. 2014;134(1):e55-62.
39. The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial. BMC Pregnancy Childbirth. 2008;8:52.
40. DeMets DL, Furberg CD, Friedman LM. Data Monitoring in Clinical Trials: A Case Studies Approach. 1 ed. New York, NY 10013, USA: Springer Science Business Media, Inc.; 2006. 374 p.
41. ICH Harmonised Guideline. Integrated addendum to ICH E6(R1). Guideline for Good Clinical Practice E6(R2), (2016).
42. Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34.
43. European Medicines Agency CfH, Products. M. Guideline on Good Clinical Practice E6(R2). 2017.
44. Hansen ML, Pellicer A, Gluud C, Dempsey E, Mintzer J, Hyttel-Sørensen S, et al. Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial. Trials. 2019;20(1):811.
45. Hein-Nielsen AL, Petersen SM, Greisen G. Unchanged incidence of necrotising enterocolitis in a tertiary neonatal department 2015 [Available from: https://ugeskriftet.dk/dmj/unchanged-incidence-necrotising-enterocolitis-tertiary-neonatal-department.
46. Statistics Denmark. Statistics Denmark 2023 [Available from: https://www.dst.dk/en.
47. Hansen ML, Pellicer A, Gluud C, Dempsey E, Mintzer J, Hyttel-Sorensen S, et al. Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants. Trials. 2019;20(1):746.
48. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120.
49. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Medical Research Methodology. 2017;17(1):162.
50. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162.
51. Pellicer A, Valverde E, Elorza MD, Madero R, Gayá F, Quero J, Cabañas F. Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial. Pediatrics. 2005;115(6):1501-12.

52. Pellicer A, Bravo MC, Madero R, Salas S, Quero J, Cabañas F. Early systemic hypotension and vasopressor support in low birth weight infants: impact on neurodevelopment. Pediatrics. 2009;123(5):1369-76.
53. Lundstrøm K, Pryds O, Greisen G. The haemodynamic effects of dopamine and volume expansion in sick preterm infants. Early Hum Dev. 2000;57(2):157-63.
54. Osborn D, Evans N, Kluckow M. Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr. 2002;140(2):183-91.
55. Trang TT, Tibballs J, Mercier JC, Beaufils F. Optimization of oxygen transport in mechanically ventilated newborns using oximetry and pulsed Doppler-derived cardiac output. Crit Care Med. 1988;16(11):1094-7.
56. Skinner JR, Boys RJ, Hunter S, Hey EN. Pulmonary and systemic arterial pressure in hyaline membrane disease. Arch Dis Child. 1992;67(4 Spec No):366-73.
57. Evans N, Kluckow M. Early determinants of right and left ventricular output in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996;74(2):F88-94.
58. Kluckow M, Evans N. Relationship between blood pressure and cardiac output in preterm infants requiring mechanical ventilation. J Pediatr. 1996;129(4):506-12.
59. Osborn DA, Evans N, Kluckow M, Bowen JR, Rieger I. Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. Pediatrics. 2007;120(2):372-80.
60. Osborn DA, Paradisis M, Evans N. The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow. Cochrane Database Syst Rev. 2007(1):Cd005090.
61. Takami T, Sunohara D, Kondo A, Mizukaki N, Suganami Y, Takei Y, et al. Changes in cerebral perfusion in extremely LBW infants during the first 72 h after birth. Pediatr Res. 2010;68(5):435-9.
62. Kissack CM, Garr R, Wardle SP, Weindling AM. Cerebral fractional oxygen extraction in very low birth weight infants is high when there is low left ventricular output and hypocarbia but is unaffected by hypotension. Pediatr Res. 2004;55(3):400-5.
63. Kleinman CS SI, Polin RA. Hemodynamics and Cardiology: Neonatology Questions and Controversies. 2008. 1-410 p. .
64. Lemmers PM, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics. 2008;121(1):142-7.
65. Jim WT, Chiu NC, Chen MR, Hung HY, Kao HA, Hsu CH, Chang JH. Cerebral hemodynamic change and intraventricular hemorrhage in very low birth weight infants with patent ductus arteriosus. Ultrasound Med Biol. 2005;31(2):197-202.
66. Wardle SP, Yoxall CW, Weindling AM. Determinants of cerebral fractional oxygen extraction using near infrared spectroscopy in preterm neonates. J Cereb Blood Flow Metab. 2000;20(2):272-9.
67. Baenziger O, Stolkin F, Keel M, von Siebenthal K, Fauchere JC, Das Kundu S, et al. The influence of the timing of cord clamping on postnatal cerebral oxygenation in preterm neonates: a randomized, controlled trial. Pediatrics. 2007;119(3):455-9.
68. Dani C, Pezzati M, Martelli E, Prussi C, Bertini G, Rubaltelli FF. Effect of blood transfusions on cerebral haemodynamics in preterm infants. Acta Paediatr. 2002;91(9):938-41.
69. Schulze A, Whyte RK, Way RC, Sinclair JC. Effect of the arterial oxygenation level on cardiac output, oxygen extraction, and oxygen consumption in low birth weight infants receiving mechanical ventilation. J Pediatr. 1995;126(5 Pt 1):777-84.

70. Cantagrel S, Cloarec S, Suc AL, Chamboux C, Tessier V, Saliba E, Laugier J. Consequences of pulmonary inflations (sighs) on cerebral haemodynamics in neonates ventilated by high-frequency oscillation. Acta Paediatr. 1999;88(9):1004-8.
71. de Waal KA, Evans N, Osborn DA, Kluckow M. Cardiorespiratory effects of changes in end expiratory pressure in ventilated newborns. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F444-8.
72. Vanderhaegen J, Naulaers G, Vanhole C, De Smet D, Van Huffel S, Vanhaesebrouck S, Devlieger H. The effect of changes in tPCO2 on the fractional tissue oxygen extraction--as measured by near-infrared spectroscopy--in neonates during the first days of life. Eur J Paediatr Neurol. 2009;13(2):128-34.
73. Dietz V, Wolf M, Keel M, v Siebenthal K, Baenziger O, Bucher H. CO2 reactivity of the cerebral hemoglobin concentration in healthy term newborns measured by near infrared spectrophotometry. Biol Neonate. 1999;75(2):85-90.
74. Pryds O, Greisen G, Skov LL, Friis-Hansen B. Carbon dioxide-related changes in cerebral blood volume and cerebral blood flow in mechanically ventilated preterm neonates: comparison of near infrared spectrophotometry and 133Xenon clearance. Pediatr Res. 1990;27(5):445-9.
75. Harris RP HM, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the U.S. Preventive Services Task Force: A review of the process. Am J Prev Med 2001; 20:21–35. .